Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.09
$0.010.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 79.00% | 76.41% | 117.54% | 98.84% | 92.77% |
| Gross Profit | -79.00% | -76.41% | -117.54% | -98.84% | -92.77% |
| SG&A Expenses | 0.02% | -7.18% | -7.78% | -2.10% | 18.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.43% | 52.60% | 75.10% | 64.32% | 66.75% |
| Operating Income | -59.43% | -52.60% | -75.10% | -64.32% | -66.75% |
| Income Before Tax | -75.84% | -68.09% | -95.32% | -74.45% | -65.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.84% | -68.09% | -95.32% | -74.45% | -65.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.84% | -68.09% | -95.32% | -74.45% | -65.72% |
| EBIT | -59.43% | -52.60% | -75.10% | -64.32% | -66.75% |
| EBITDA | -60.14% | -53.61% | -76.75% | -65.79% | -68.22% |
| EPS Basic | -29.66% | -37.61% | -63.14% | -17.43% | 18.15% |
| Normalized Basic EPS | -22.61% | -29.14% | -51.39% | -24.42% | 12.51% |
| EPS Diluted | -29.66% | -37.61% | -63.14% | -17.43% | 18.15% |
| Normalized Diluted EPS | -22.61% | -29.14% | -51.39% | -24.42% | 12.51% |
| Average Basic Shares Outstanding | 37.56% | 25.90% | 22.21% | 36.67% | 72.40% |
| Average Diluted Shares Outstanding | 37.56% | 25.90% | 22.21% | 36.67% | 72.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |